Effects of rosuvastatin at different treatment times on patients with acute cerebral infarction

Abstract

Objective To evaluate the efficacy of rosuvastatin at different treatment timings on symptomatic intracranial hemorrhage, laboratory indexes and good outcome rate of patients with acute cerebral infarction treated with intravenous thrombolysis. Methods A total of 150 patients with acute cerebral infarction treated in Neurology Department of Jiaozhou People’s Hospital from March 2017 to February 2018 were selected and were divided into pre-thrombolysis group (group A, 75 cases) and post-thrombolysis group (group B, 75 cases) according to the random number table method. Patients in both groups were given intravenous thrombolysis with alteplase after admission. Patients in group A were given rosuvastatin tablets orally within 24 h before thrombolytic therapy. Patients in group B were given rosuvastatin tablets orally within 24 h after thrombolytic therapy. The good outcome rate, ADL-Barthel, National Institute of Health stroke scale (NIHSS) scores, levels of interleukin 17(IL-17), matrix metalloproteinase 9(MMP-9) and high mobility group box 1(HMGB1) were compared between the two groups before treatment and at 1 week and 8 weeks after thrombolytic therapy. The incidence of intracranial hemorrhage and the incidence of adverse reactions were compared between the two groups. Results The good outcome rate at 1 week and 8 weeks after treatment of group A (53.3%, 81.3%) was significantly higher than that in group B (30.7%, 60.0%), respectively(χ2=7.909, 8.233; P=0.005, 0.005). After treatment, the ADL-Barthel index, NIHSS score, levels of IL-17, MMP-9, and HMGB1 were significantly improved in both groups (all P<0.05), and ADL-Barthel index, NIHSS score, levels of IL-17, MMP-9 and HMGB1 in group B were superior to those in group A (all P<0.05). There was no significant difference in the incidence of intracranial hemorrhage between group A and group B (53.3% vs. 30.7%, χ2=0.132, P=0.716). Conclusions For the patients with acute cerebral infarction treated by intravenous thrombolytic therapy, giving rosuvastatin before thrombolytic therapy can significantly improve the prognosis, promote quality of life and recovery of neurological function, reduce the level of IL-17, MMP-9 and HMGB1, without increasing in the risk of intracranial hemorrhage. It is safe and worthy of clinical application. Key words: Acute cerebral infarction; Thrombolysis; Rosuvastatin; Timing of treatment